Login to Your Account



Intercell Plunges on Phase III Miss; Restructuring to Come

By Cormac Sheridan


Tuesday, December 14, 2010
Shares in Intercell AG plummeted 40 percent Monday on news that its patch-based vaccine for traveler's diarrhea failed to demonstrate efficacy in two studies, a Phase III trial in Central America and a Phase II pilot study in India.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription